Mapi Research Trust

What Mapi Research Trust does

Mapi Research Trust is a French-registered non-profit organization founded in 1995 and headquartered in Lyon, with an additional office in Leopardstown, Ireland, that facilitates global access to Clinical Outcome Assessments (COAs). The organization's mission centers on improving patients' quality of life by collecting, curating, and distributing patient-centered outcome information on behalf of questionnaire developers and copyright holders, with 30+ years of accumulated expertise in the field. It operates as an ICON business under the governance of ICON Clinical Research Limited (the publicly traded parent ICON plc) while maintaining an independent non-profit status.

The core technology is the ePROVIDE online platform, which centralizes three proprietary databases — PROQOLID (9,000+ COAs described in detail, the largest such catalog), PROLABELS (2,400+ label claims documenting how patient-reported outcomes have been incorporated into drug approvals), and PROINSIGHT (300+ regulatory guidelines) — alongside COA licensing, translation and linguistic validation, eCOA migration and certification, targeted literature review (Patient-Centered Endpoint Intelligence), and a COA Repository workspace. Mapi Research Trust is the exclusive distributor for 800+ COAs and supports multi-decade partnerships with Wiley, Springer Nature, GL Assessment, MSD/Merck Sharp & Dohme, the PANSS Institute, Observia, WCG, and numerous academic institutions and patient advocacy organizations.

Revenue is generated primarily through COA licensing fees (both royalty fees for copyrighted COAs and service fees for public-domain COAs), translation and linguistic validation projects, eCOA migration and certification services, and targeted literature reviews, with quote-based per-transaction pricing for commercial sponsors and healthcare organizations. A freemium tier provides free access for non-funded academic researchers and reduced fees for funded academics, which supports a network of 3,500+ researchers and health-authority representatives and processes 20,000+ information requests per year. Primary customer segments are pharmaceutical and biotech sponsors of clinical trials, academic and independent researchers, healthcare organizations and hospitals, and rare-disease researchers.

Name

Mapi Research Trust

Legal name

Mapi Research Trust

Website

https://mapi-trust.org

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

51–100 employees

Short description

Mapi Research Trust is a French non-profit that facilitates global access to Clinical Outcome Assessments (COAs) through its ePROVIDE platform, exclusively distributing 800+ COAs and serving pharmaceutical, academic, and healthcare customers in clinical research.

Ownership category

akta.pro rank

Product category

Clinical Outcome Assessments (COA)

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Consent, Preference & Data Rights Management (incl. HIPAA/GDPR support) (HLACAIAG)

Keywords

• Clinical outcome assessments
• Patient-reported outcomes
• COA licensing services
• Linguistic validation
• ECOA digitization

Headquarters

HQ city

Leopardstown

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. COA Licensing Services: Fees for licensing COAs for use in clinical trials, including access to official original versions, validated translations, scoring methods, and interpretation guidance. Both copyrighted COAs (royalty and service fees) and public domain COAs (service fees) incur charges.
2. Academic Access - Free Tier: Free access to all COAs from the distribution catalog (original versions, translations, and electronic versions) for non-funded academic researchers. Funded academic researchers benefit from reduced fees.
3. Translation and Linguistic Validation Services: Coordination of translation projects for COAs requiring linguistic validation to ensure measurement property equivalence across languages
4. eCOA Licensing and Implementation Services: Services for digitization of paper COAs including best practice guidance, screenshot review and certification, and expert review for electronic capture of data

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Mapi Research Trust is a non-profit organization that facilitates access to Clinical Outcome Assessments (COAs) by serving as the exclusive distributor for 800+ COAs on behalf of copyright holders and developers. Through its centralized ePROVIDE™ platform, it provides COA licensing, translation and linguistic validation, eCOA digitization and certification, and patient-centered endpoint intelligence (targeted literature reviews) to pharmaceutical sponsors, academic researchers, and healthcare organizations worldwide.

Product overview

Mapi Research Trust is a non-profit organization offering a comprehensive portfolio of COA (Clinical Outcome Assessment) services through its centralized ePROVIDE™ platform. The portfolio consists of three interconnected databases (PROQOLID™ with 9,000+ COA descriptions, PROLABELS™ with 2,400+ label claims, and PROINSIGHT™ with 300+ regulatory guidelines) alongside core services including COA Licensing (streamlined licensing for any COA), Patient-Centered Endpoint Intelligence (targeted literature reviews for endpoint selection), Translation and Linguistic Validation, eCOA Licensing (digitization and certification), and COA Repository. Mapi Research Trust serves as the exclusive distributor of 800+ COAs, managing distribution, licensing, and protection of questionnaire assets on behalf of developers and copyright holders.

Differentiator

Problem solved

Functional benefit

Brands

• ePROVIDE: Online platform providing access to COA databases and services including PROQOLID, PROLABELS, and PROINSIGHT
• PROQOLID
• PROLABELS
• PROINSIGHT

Products and services

• ePROVIDE™

Quantifiable outcome

• Streamlined licensing reduces burden for sponsors through single point of contact
• +2 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

21 partnerships are on record, tiered minor, core and flagship.

• Université LavalminorChannel Partner/ Reseller/ Distributor · 4 June 2026Université Laval entrusted MRT with management of their COAs including the Fear of Cancer Recurrence Inventory (FCRI) and FCRI-SF.
• Université de Montréal and Institut universitaire de gériatrie de MontréalminorChannel Partner/ Reseller/ Distributor · 1 April 2026Academic institutions entrusted MRT with management of the QUEST 2.0 questionnaire for measuring user satisfaction with assistive technologies.
• Dr. Jesse CedarbaumminorChannel Partner/ Reseller/ Distributor · 27 January 2026Dr. Cedarbaum works with MRT to manage distribution of the ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised) for evaluating disability progression in ALS patients.
• Friedreich's Ataxia Research Alliance (FARA)minorChannel Partner/ Reseller/ Distributor · 21 August 2025FARA entrusted MRT with management of 5 COAs developed for Friedreich's ataxia, a rare genetic and progressive neuromuscular disease affecting approximately 15,000 individuals worldwide.
• PANSS InstitutecoreChannel Partner/ Reseller/ Distributor · 3 March 2025Authors of the PANSS (Positive and Negative Syndrome Scale for Schizophrenia) appointed MRT as their exclusive licensing and distribution partner.
• QOL Technologies Ltd.coreChannel Partner/ Reseller/ Distributor · 25 November 2024Partnership for management of QOL Technologies' COAs. All requests for use are sent directly to Mapi Research Trust via the ePROVIDE platform.
• South London and Maudsley NHS Foundation TrustcoreChannel Partner/ Reseller/ Distributor · 24 November 2024NHS Foundation Trust entrusted MRT with exclusive distribution and licensing of the SDS-Gossop and SOWS-Gossop questionnaires.
• Professor Ewa Roos (University of Southern Denmark)coreChannel Partner/ Reseller/ Distributor · 10 October 2023Professor Roos entrusted MRT with management of the KOOS, HOOS, FAOS and their derivatives. These are gold standard instruments in joint injury and osteoarthritis assessment, developed over 20 years ago and widely used in clinical trials.
• Springer NaturecoreStrategic or Co-development Partner · 6 April 2023Partnership for distribution of Clinical Outcome Assessments and management of licensing requests. MRT brings 30 years of experience to manage all licensing requests and support COA users with appropriate information and essential materials for proper use.
• Merck Sharp & Dohme LLC (MSD)coreChannel Partner/ Reseller/ Distributor · 5 December 2022MRT serves as exclusive partner for licensing and distribution of MSD's COA measures including management of translations and electronic versions. Joint development of MSD's dedicated COA website (msdpatientmeasures.com).
• ObserviacoreChannel Partner/ Reseller/ Distributor · 24 November 2022Exclusive partnership for licensing and distribution of the SPUR (context of clinical research not located in Greater China) Adherence Profiling Tool.
• WCG Clinical Endpoint SolutionscoreStrategic or Co-development Partner · 6 September 2022MRT supports WCG in the development of 27 electronic versions (eCOA) of Clinical Outcome Assessments for their eCOA library.
• SKEZIminorStrategic or Co-development Partner · 5 July 2022Partnership to accelerate acquisition and sharing of health data from patients for use in clinical research and routine care settings.
• WileyflagshipChannel Partner/ Reseller/ Distributor · 1 January 2022Longstanding partnership for distribution of 45 COAs whose rights are managed by Wiley on behalf of professional societies. MRT supports distribution of questionnaires and manages all user requests to access original COAs, scoring guides, validated translations, and electronic versions.
• Orphanet-INSERM / ERICA ConsortiumflagshipStrategic or Co-development Partner · 1 January 2020EU-funded 4-year grant partnership (European Rare disease research Coordination and Support Action) to analyze and code functional consequences of rare diseases and identify validated COAs that measure functional impacts. MRT provides expertise in identifying appropriate measurement instruments for rare disease research.
• ICON Language ServicescoreStrategic or Co-development PartnerCollaboration for coordination of translation projects, ensuring rigorous linguistic validation processes for COA translations to maintain measurement property equivalence across languages.
• ICON plccoreOthersMRT is an ICON business and not-for-profit organization registered under French law. ICON provides governance and infrastructure support while MRT maintains independent operations focused on its mission.
• GL AssessmentminorChannel Partner/ Reseller/ DistributorPartnership for management of COAs developed by GL Assessment.
• InflexxionminorChannel Partner/ Reseller/ DistributorExclusive licensing and distribution agreement for Inflexxion's scales.
• Center for Environmental TherapeuticsminorChannel Partner/ Reseller/ DistributorMRT is exclusive distributor of CET's scales.
• Philip Morris InternationalminorChannel Partner/ Reseller/ DistributorMRT provides access to the ABOUT™-Toolbox, a portfolio of self-report instruments for tobacco and nicotine product assessment developed in collaboration with Philip Morris International.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• IQVIA: IQVIA offers eCOA and patient-reported outcome services within its broader CRO platform and competes with MRT on regulatory-grade COA selection, licensing, and translation services for global pharma sponsors.
• Medidata (Dassault Systèmes): Medidata's Patient Cloud and Rave EDC ecosystem host and license eCOA instruments at scale. Its instrument library positioning is an adjacent substitute for sponsors that prefer platform-native COA sourcing over a distributor like MRT.
• Clario (formerly CRF Health / ERT): Clario is the largest eCOA platform provider, building proprietary instrument libraries and licensing relationships with COA developers. Its eCOA solutions compete with MRT's eCOA licensing, certification, and digitization services within the same pharmaceutical sponsor workflow.
• Signant Health: Signant Health provides a full eCOA suite (Build, Drive, TrialMax) and licenses its own and third-party instruments, competing with MRT on electronic implementation of patient-reported outcomes in regulated clinical trials.

Direct peers

• Critical Path Institute (C-Path): C-Path develops and stewards qualified Clinical Outcome Assessments and biomarker tools, and runs PRO consortia that compete with MRT's role as a long-term custodian and licensor of disease-specific COAs for regulatory use.
• WCG (WCG Clinical Endpoint Solutions): WCG develops eCOA libraries in collaboration with MRT (27 electronic versions as of 2022) but also originates and licenses COAs independently, serving as both a partner and a partial competitor for sponsor endpoint strategies.
• FACITtrans: FACIT.org operates FACITrans, one of the principal translation and linguistic-validation providers for Clinical Outcome Assessments, competing head-to-head with Mapi Research Trust on cross-language COA adaptation services for pharma sponsors.

Emerging players

• Clinical Ink: Clinical Ink builds electronic Clinical Outcome Assessment (eCOA) and patient-centric data capture tools, competing for the same digitization business that feeds MRT's eBooklets and eCOA licensing services.

Regional players

• Vector Oncology: Vector Oncology provides PRO measurement and COA development services focused on oncology trials, partially overlapping with Mapi Research Trust's CAT/FDA-PRO work in cancer endpoints such as the Fear of Cancer Recurrence Inventory licensed from Université Laval.

Others

• Pharmaprojects / Citeline: Citeline and similar data/analytics vendors track COA usage across clinical trials, creating pipeline-intelligence products. While not a direct competitor, they overlap thematically as repositories and reference layers for trial endpoints.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/mapiresearchtrust
• Xx.com/Mapi_Trust

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mapi Research Trust